A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 29
- 试验地点
- 3
- 主要终点
- Incidence of Dose Limiting Toxicities
研究概览
简要总结
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or RP2D of the orally administered PI3K/mTOR inhibitor BEZ235 in combination with the MEK1/2 inhibitor MEK162. This combination will be explored in patients with EGFR mutant NSCLC which has progressed on EGFR inhibitors and triple negative breast cancer, as well as pancreatic cancer, colorectal cancer, malignant melanoma, NSCLC, and other advanced solid tumors with KRAS, NRAS, and/or BRAF mutations. Dose escalation will be guided by a Bayesian logistic regression model with overdose control. At MTD or RP2D, two expansion arms will be opened in order to further assess safety and preliminary anti-tumor activity of the combination of BEZ235 and MEK162.
Study drugs will be administered orally on a continuous schedule, MEK162 bid and BEZ235 qd, a treatment cycle is defined as 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically/cytologically confirmed, advanced non resectable solid tumors
- •Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0
排除标准
- •Patients with primary CNS tumor or CNS tumor involvement
- •Diabetes mellitus - Unacceptable ocular/retinal conditions
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
BEZ235 + MEK162
干预措施: BEZ235 + MEK162 (Drug)
结局指标
主要结局
Incidence of Dose Limiting Toxicities
时间窗: during Cycle 1 of treatment with BEZ235 and MEK162
A complete treatment cycle is defined as 28 days of daily continuois treatment with study drug combination
次要结局
- Time versus plasma concentration profiles of BEZ235 and MEK162(during the first cycle of treatment)
- Overall response rate, duration of response, time to response and progression free survival(every 8 weeks of treatment)
- Treatment-induced PI3K and MEK/ERK pathway signaling inhibition and evidence of biological activity in tumor(during the first cycle of treatment and at disease progression)
- Number of participants with adverse events and serious adverse events(from Cycle 1 Day 1 until treatment discontinuation)